Diabetes Medications Used for Cardiovascular Conditions

Home
»
2025 National Conference
»
Product Details

You must select a location to proceed.

Yes

There was a problem adding this course to your account. Please try again in a few minutes. If the problem persists, you can contact our support department at (877) 880-1335.

Adding Registration, Please wait...

You must be logged in to perform this action.

Cancel

Diabetes Medications Used for Cardiovascular Conditions

Recorded for 2025 National Conference

Credit(s):

0.97 Contact Hour(s) of CE; all of which may be applied towards Pharmacology

Program Number:

25067274

Original Program Date:

June 27, 2025

Duration:

58 minutes

Access:

Available until July 15, 2026

Special Offer

Click here to see Special Offer(s)!

Facebook

E-Mail

Description
Sessions
Credits
Faculty
Materials
Reviews
Dates and Locations

(76)

Read Reviews

Category: 2025 National Conference, Cardiometabolic, Cardiovascular ... (show more)

Category: 2025 National Conference, Cardiometabolic, Cardiovascular, Cert Exam Domain - Evaluation, Cert Exam Domain - Planning, Diabetes Mellitus, Endocrine, Family, Nephrology, Optum Recommended Education, Outpatient, Recent Additions (show less)

Activity Duration

Content Expires:

July 15, 2026 (11:55 p.m. CT)
CE for this activity will not be available after this date.

This CE activity was recorded for the 2025 AANP National Conference.

This activity includes closed captioning.

Delivery Note: The content for this activity was previously presented during the 2025 AANP National Conference. If you already completed the content of this activity while attending the live or virtual conference, you should not complete this content a second time. Learners should only complete ONE delivery-method to earn credit. Completing multiple delivery options for the same activity is considered duplicate credit for the same content and will not be accepted by regulatory bodies.

Overview
After the FDA required long-term cardiovascular outcomes trials (CVOTs) for all new diabetes agents in 2009 to ensure safety, the results of CVOTs demonstrated positive outcomes that favored heart and kidney protection in additional to glucose lowering. These unexpected results have led to new indications for many of these newly approved agents, and several of them can now be used for patients who do not have type 2 diabetes. Another unexpected trend for many of the newer agents typically used for type 2 diabetes is that practitioners other than endocrinology or primary care are prescribing them. These changes reflect a needed shift in focus away from a traditional gluco-centric view for people with diabetes. Due to the bidirectional relationship that diabetes shows with cardiovascular risks and/or disease and chronic kidney disease, treatment guidelines are endorsing a more outcome-oriented approach to diabetes management. Therefore, this session will review the evidence for sodium glucose co-transporter inhibitors (SGLT2is) and their positive influence on reduced hospitalization and deaths attributed to heart failure as well as reduced nephropathy. In addition, the evidence favoring GLP-1s for the reduction in macrovascular and renal complications will be discussed.

Objectives

Describe the rationale for the FDA’s guidance for long-term cardiovascular outcomes trials for anti-diabetic agents.
Review the new, less glucocentric approach to managing patients with metabolic-cardiovascular-renal disorders.
Discuss select SGLT2 inhibitors’ mechanisms of action that are theorized to provide renal and cardiovascular protection.
Identify the underlying mechanism of major adverse cardiovascular event reduction afforded by select GLP-1 receptor agonists.

Speakers
Jane Kapustin, PhD, CRNP, BC-ADM, FAANP, FAAN
Shannon Idzik, DNP, ANP-BC, FAANP, FAAN

Disclosure
This program was planned in accordance with AANP CE Standards and Policies.

The speakers have the following disclosures:

Jane Kapustin
- Speaker for Sanofi (type 1 monoclonal antibody, Tzield)
- Advisory board for Sanofi (insulin)
- Speaker for Simplicity Cequr (insulin delivery device)
Shannon Idzik:
- No disclosures.

All relevant financial relationships have been mitigated.

Disclaimer
Individuals who have contributed to the CE Center (content originally from the 2025 AANP National Conference) were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

CE Credit Instructions

Read this activity description, including objectives and disclosures.
Complete all educational content:
- OnDemand Presentations: Click the Play button to watch the activity video lecture. To get full credit for the learning activity portion, you must watch all of the video content.
- Click on the Additional Resources button to review all additional materials provided (handouts and any other downloadable resources).
After completing all educational content, go to the Next Steps button:
- Submit the activity evaluation to receive full AANP CE/Rx credit.
- Click on the Get Certificate button. At the top of the certificate screen, use the provided dropdown menu and select AANP Certificate of Completion.
  - A copy of your certificate of completion will display on the screen for you to print or save. A copy of the certificate will also be emailed to you.
  - A copy of the certificate will be automatically added to your AANP CE Tracker.

Additional Information
For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.

0.97 Contact Hour(s) of CE,
All of which may be applied towards Pharmacology